Why Is ULTRAGENYX PHARMACEU (RARE) Stock Moving Today?

Why RARE stock is moving today

Ultragenyx Pharmaceutical (RARE) is moving lower today amid a wave of downgrades and a failed clinical trial. The stock opened with a modest gap up but has since fallen into a downward trend, trading at $15.40 with a session high of $16.08. The decline follows the company's announcement that its Phase 3 Aspire study for apazunersen in Angelman syndrome failed to meet key endpoints. This setback has increased risk for the rare disease specialist and triggered multiple analyst downgrades.

What Happened

Ultragenyx shares are under pressure after the failed Angelman syndrome trial, which is a key therapeutic area for the company. Morgan Stanley downgraded the stock to Equal Weight from Overweight, while Barclays cut its price target to $32 from $43. Jefferies and JP Morgan also reduced their price targets, with JP Morgan setting a new target of $36. Goldman Sachs maintained a neutral stance but lowered its price target to $19. These developments have contributed to a broader sense of pessimism in the market.

The stock has fallen sharply over the past eight sessions, dropping 39.9% from $26.24 to $15.77. This comes as insiders, including the CFO and an executive vice president, have sold shares in recent months. The sentiment trend has also deteriorated, with the 30-day average at 45/100 and the last seven days at 34/100.

What The Data Shows

Intraday trading has shown a volatile session, with the stock opening at $15.10 and reaching a high of $16.08 before retreating. Volume has surged to 9.9 million shares, nearly 4.5 times the 3-month average. The 52-week tape has recorded six fresh 52-week lows and six highs on September 4, reflecting the stock's extreme price swings. Unusual options activity has also been noted, with $716K in call premiums traded over the last 36 hours.

What To Watch

Ultragenyx has no scheduled earnings date in the immediate future. Investors will need to monitor coverage breadth and any further analyst actions as the stock remains under pressure from both clinical setbacks and shifting analyst sentiment.